Three-Drug Regimen After Transplant May Improve Relapse-Free Survival in GVHD

Adults with graft-versus-host disease who were treated with a three-drug regimen with cyclophosphamide after transplant may have improved survival rate compared with those treated with a two-drug regimen.

Patients treated with a three-drug regimen — cyclophosphamide, tacrolimus and mycophenolate mofetil — after undergoing a stem cell transplant had increased one-year graft-versus-host disease (GVHD) relapse-free survival compared with those treated with a two-drug regimen, according to findings from a phase 3 trial. Read more in Cure Today.